PFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pfizer's cash flow for dividends for the three months ended in Dec. 2023 was $-2,315 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was $-9,247 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
Pfizer's quarterly payment of dividends declined from Jun. 2023 ($-2,315 Mil) to Sep. 2023 ($-2,314 Mil) but then increased from Sep. 2023 ($-2,314 Mil) to Dec. 2023 ($-2,315 Mil).
Pfizer's annual payment of dividends increased from Dec. 2021 ($-8,729 Mil) to Dec. 2022 ($-8,983 Mil) and increased from Dec. 2022 ($-8,983 Mil) to Dec. 2023 ($-9,247 Mil).
The historical data trend for Pfizer's Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9,247 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pfizer's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott Gottlieb | director | MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142 |
Christoffel Boshoff | officer: Executive Vice President | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Jennifer B. Damico | officer: SVP & Controller | C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Payal Sahni | officer: Executive Vice President | ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
Carapezzi William R Jr | officer: Executive Vice President | 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921 |
Douglas M Lankler | officer: Senior Vice President | PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Mikael Dolsten | officer: Senior Vice President | 5 GIRALDA FARMS, MADISON NJ 07940 |
David M Denton | officer: Chief Financial Officer & EVP | 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117 |
William Pao | officer: Executive Vice President | C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Michael Mcdermott | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017 |
Rady A Johnson | officer: Executive Vice President | PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Alexander R Mackenzie | officer: Executive Vice President | C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Sally Susman | officer: Senior Vice President | 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153 |
Angela Hwang | officer: Group President | 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017 |
John D Young | officer: Business Unit President | C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
From GuruFocus
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-24-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.